Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1986 Jul;88(3):595–605. doi: 10.1111/j.1476-5381.1986.tb10240.x

Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4.

P J Piper, A G Stewart
PMCID: PMC1916979  PMID: 3091131

Abstract

Platelet-activating factor (Paf, 0.04-4.50 nmol) dose-dependently induced coronary vasoconstriction and decreased cardiac contractility in rat, isolated perfused hearts and concomitantly released leukotriene-like bioactivity into the cardiac effluent. Platelet-activating factor (0.9 nmol) induced an increase in 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), PGF2 alpha, PGE2 and thromboxane B2 (TXB2) measured by radioimmunoassay (RIA) of cardiac effluents following partial purification using C18 Sep-Paks. The leukotriene-like bioactivity released by Paf was identified as leukotriene C4 (LTC4) using a combination of isolation on reverse phase-h.p.l.c. (r.p.h.p.l.c.) and quantitation by RIA. In addition, LTB4 was also identified by r.p.h.p.l.c. and the levels, determined by RIA, were within the range having biological activity. The release of cyclo-oxygenase products by Paf was prevented by indomethacin (2.8 microM), markedly attenuated by diethylcarbamazine (7.7 mM) but unaffected by FPL 55712 (1.9 microM)-pretreatment. Furthermore, LTC4 (50 pmol) did not increase the release of the cyclo-oxygenase products measured. The release of LTB4 and LTC4 appeared to be unaffected by indomethacin pretreatment whereas diethylcarbamazine-pretreatment markedly inhibited release. The coronary vasoconstriction induced by Paf (0.9 nmol) was attenuated by pretreatment with indomethacin or diethylcarbamazine, whereas FPL 55712 caused a marked inhibition of the response. In contrast, the decrease in cardiac contractility was prevented by indomethacin or diethylcarbamazine and unaffected by FPL 55712 pretreatment. It is concluded that LTC4 may be largely responsible for the coronary vasoconstriction induced by Paf with cyclo-oxygenase products having a possible modulatory role whereas the latter appear to be involved in the Paf-induced decrease in cardiac contractility.

Full text

PDF
595

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aehringhaus U., Dembinska-Kiéc A., Peskar B. A. Effects of exogenous prostaglandins on the release of leukotriene C4-like immunoreactivity and on coronary flow in indomethacin-treated anaphylactic guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jul;326(4):368–374. doi: 10.1007/BF00501445. [DOI] [PubMed] [Google Scholar]
  2. Allan G., Levi R. Thromboxane and prostacyclin release during cardiac immediate hypersensitivity reactions in vitro. J Pharmacol Exp Ther. 1981 Apr;217(1):157–161. [PubMed] [Google Scholar]
  3. Anhut H., Bernauer W., Peskar B. A. Pharmacological modification of thromboxane and prostaglandin release in cardiac anaphylaxis. Prostaglandins. 1978 May;15(5):889–900. doi: 10.1016/0090-6980(78)90156-9. [DOI] [PubMed] [Google Scholar]
  4. Beaubien B. B., Tippins J. R., Morris H. R. Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide. Biochem Biophys Res Commun. 1984 Nov 30;125(1):105–108. doi: 10.1016/s0006-291x(84)80340-x. [DOI] [PubMed] [Google Scholar]
  5. Benveniste J., Boullet C., Brink C., Labat C. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol. 1983 Sep;80(1):81–83. doi: 10.1111/j.1476-5381.1983.tb11052.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Camussi G., Aglietta M., Malavasi F., Tetta C., Piacibello W., Sanavio F., Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983 Nov;131(5):2397–2403. [PubMed] [Google Scholar]
  7. Engineer D. M., Niederhauser U., Piper P. J., Sirois P. Release of mediators of anaphylaxis: inhibition of prostaglandin synthesis and the modification of release of slow reacting substance of anaphylaxis and histamine. Br J Pharmacol. 1978 Jan;62(1):61–66. doi: 10.1111/j.1476-5381.1978.tb07006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ford-Hutchinson A. W., Bray M. A., Doig M. V., Shipley M. E., Smith M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. doi: 10.1038/286264a0. [DOI] [PubMed] [Google Scholar]
  9. Hayes E. C., Lombardo D. L., Girard Y., Maycock A. L., Rokach J., Rosenthal A. S., Young R. N., Egan R. W., Zweerink H. J. Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J Immunol. 1983 Jul;131(1):429–433. [PubMed] [Google Scholar]
  10. Heffner J. E., Shoemaker S. A., Canham E. M., Patel M., McMurtry I. F., Morris H. G., Repine J. E. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. J Clin Invest. 1983 Feb;71(2):351–357. doi: 10.1172/JCI110776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jose P., Niederhauser U., Piper P. J., Robinson C., Smith A. P. Degradation of porstaglandin F2alpha in the human pulmonary circulation. Thorax. 1976 Dec;31(6):713–719. doi: 10.1136/thx.31.6.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kenzora J. L., Pérez J. E., Bergmann S. R., Lange L. G. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest. 1984 Oct;74(4):1193–1203. doi: 10.1172/JCI111528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lefer A. M., Müller H. F., Smith J. B. Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol. 1984 Sep;83(1):125–130. doi: 10.1111/j.1476-5381.1984.tb10126.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lefer A. M., Roth D. M., Lefer D. J., Smith J. B. Potentiation of leukotriene formation in pulmonary and vascular tissue. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jun;326(2):186–189. doi: 10.1007/BF00517318. [DOI] [PubMed] [Google Scholar]
  15. Letts L. G., Piper P. J. Cardiac actions of leukotrienes B4, C4, D4, and E4 in guinea pig and rat in vitro. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:391–395. [PubMed] [Google Scholar]
  16. Levi R., Burke J. A., Guo Z. G., Hattori Y., Hoppens C. M., McManus L. M., Hanahan D. J., Pinckard R. N. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res. 1984 Feb;54(2):117–124. doi: 10.1161/01.res.54.2.117. [DOI] [PubMed] [Google Scholar]
  17. Lynch J. M., Lotner G. Z., Betz S. J., Henson P. M. The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol. 1979 Sep;123(3):1219–1226. [PubMed] [Google Scholar]
  18. Morganroth M. L., Stenmark K. R., Zirrolli J. A., Mauldin R., Mathias M., Reeves J. T., Murphy R. C., Voelkel N. F. Leukotriene C4 production during hypoxic pulmonary vasoconstriction in isolated rat lungs. Prostaglandins. 1984 Dec;28(6):867–875. doi: 10.1016/0090-6980(84)90040-6. [DOI] [PubMed] [Google Scholar]
  19. Mullane K. M., Read N., Salmon J. A., Moncada S. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther. 1984 Feb;228(2):510–522. [PubMed] [Google Scholar]
  20. Piper P. J., Letts L. G., Galton S. A. Generation of a leukotriene-like substance from porcine vascular and other tissues. Prostaglandins. 1983 Apr;25(4):591–599. doi: 10.1016/0090-6980(83)90031-x. [DOI] [PubMed] [Google Scholar]
  21. Piper P. J., Temple D. M. The effect of lipoxygenase inhibitors and diethylcarbamazine on the immunological release of slow reacting substance of anaphylaxis (SRS-A) from guinea-pig chopped lung. J Pharm Pharmacol. 1981 Jun;33(6):384–386. doi: 10.1111/j.2042-7158.1981.tb13810.x. [DOI] [PubMed] [Google Scholar]
  22. RANG H. P. STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLE. Br J Pharmacol Chemother. 1964 Apr;22:356–365. doi: 10.1111/j.1476-5381.1964.tb02040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Salmon J. A., Simmons P. M., Palmer R. M. A radioimmunoassay for leukotriene B4. Prostaglandins. 1982 Aug;24(2):225–235. doi: 10.1016/0090-6980(82)90148-4. [DOI] [PubMed] [Google Scholar]
  24. Sautebin L., Viganò T., Grassi E., Crivellari M. T., Galli G., Berti F., Mezzetti M., Folco G. Release of leukotrienes, induced by the Ca++ ionophore A23187, from human lung parenchyma in vitro. J Pharmacol Exp Ther. 1985 Jul;234(1):217–221. [PubMed] [Google Scholar]
  25. Sybertz E. J., Watkins R. W., Baum T., Pula K., Rivelli M. Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog. J Pharmacol Exp Ther. 1985 Jan;232(1):156–162. [PubMed] [Google Scholar]
  26. Terashita Z., Imura Y., Nishikawa K., Sumida S. Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol. 1985 Feb 26;109(2):257–261. doi: 10.1016/0014-2999(85)90427-3. [DOI] [PubMed] [Google Scholar]
  27. Voelkel N. F., Stenmark K. R., Reeves J. T., Mathias M. M., Murphy R. C. Actions of lipoxygenase metabolites in isolated rat lungs. J Appl Physiol Respir Environ Exerc Physiol. 1984 Sep;57(3):860–867. doi: 10.1152/jappl.1984.57.3.860. [DOI] [PubMed] [Google Scholar]
  28. Voelkel N. F., Worthen S., Reeves J. T., Henson P. M., Murphy R. C. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science. 1982 Oct 15;218(4569):286–289. doi: 10.1126/science.7123233. [DOI] [PubMed] [Google Scholar]
  29. Watts I. S., Zakrzewski J. T., Bakhle Y. S. Altered prostaglandin synthesis in isolated lungs of rats with streptozotocin-induced diabetes. Thromb Res. 1982 Nov 1;28(3):333–342. doi: 10.1016/0049-3848(82)90115-3. [DOI] [PubMed] [Google Scholar]
  30. de Deckere E. A., Nugteren D. H., Ten Hoor F. Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature. 1977 Jul 14;268(5616):160–163. doi: 10.1038/268160a0. [DOI] [PubMed] [Google Scholar]
  31. de Deckere E. A., ten Hoor F. PGF2 alpha stimulates release of PGE2 and PGI2 in the isolated perfused rat heart. Adv Prostaglandin Thromboxane Res. 1980;7:655–658. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES